Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCK | P35557 | 5/20 | 0.56 |
| ▸ | PPIA | P62937 | 4/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | USP28 | Q96RU2 | 1/20 | 0.43 |
| ▸ | USP25 | Q9UHP3 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | LRRK2 | Q5S007 | 4/20 | 0.42 |
| ▸ | CCR5 | P51681 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2340858 | 0.83 | NPC1 (0.68) | GCKALDH1A1NPC1KCNH2 | |
| SCHEMBL1327994 | 0.82 | GCK (0.54) | GCKALDH1A1NPC1KCNH2 | |
| SCHEMBL26151208 | 0.79 | GCK (0.57) | GCKALDH1A1USP28USP25HTT | |
| SCHEMBL2335868 | 0.79 | PPIA (0.64) | GCKPPIA | |
| SCHEMBL6833701 | 0.78 | ALDH1A1 (0.44) | GCKALDH1A1NPC1KCNH2 | |
| SCHEMBL2341214 | 0.78 | PPIA (0.44) | GCKPPIAALDH1A1GAANPC1 | |
| SCHEMBL190760 | 0.77 | ALDH1A1 (0.43) | ALDH1A1GAALRRK2CCR5 | |
| SCHEMBL2337875 | 0.77 | MAPKAPK2 (0.40) | GCKPPIAALDH1A1GAAKCNH2 | |
| SCHEMBL15685406 | 0.76 | GCK (0.55) | GCKALDH1A1USP28USP25HTT | |
| SCHEMBL2436153 | 0.75 | GCK (0.49) | GCKUSP28USP25HTTLRRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8933077-B2 | Glucokinase activators | ARRAY BIOPHARMA INC. (US) | 2015-01-13 | — | — | US | disclosed |
| EP-1948652-B1 | GLUCOKINASE ACTIVATORS | ARRAY BIOPHARMA INC (US) | 2011-08-24 | — | — | EP | disclosed |
| US-20100056530-A1 | GLUCOKINASE ACTIVATORS | ARRAY BIOPHARMA INC. (US) | 2010-03-04 | — | — | US | disclosed |
| EP-1948652-A1 | GLUCOKINASE ACTIVATORS | Array Biopharma, Inc. (US) | 2008-07-30 | — | — | EP | disclosed |
| WO-2007053345-A1 | GLUCOKINASE ACTIVATORS | ARRAY BIOPHARMA INC. (US) | 2007-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056530-A1 | GLUCOKINASE ACTIVATORS | GCKR, GCK, GALK1 | GCK 2/4885PPIA 3953/4885ALDH1A1 1377/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.